









































This millennium meeting was held at Imperial College,
London, UK, 24th–27th September 2000. Celebrating the
return of this biannual meeting to the city of its very first
meeting, 300 participants from around the world attended
plenary lectures, a workshop session and presented 150
posters over two sessions.
Two award lectures were given: the Paget-Ewing award
lecture was given by Isaiah Fidler (University of Texas MD
Anderson Cancer Center, Houston, USA) who gave an
overview of the recent developments in the “seed and soil”
hypothesis; Stephen Carter (Sugen, USA) gave the Kurt
Hellmann award lecture, a new award in honour of those
who have made an outstanding contribution in translating
the problems of research in metastatic disease from the
laboratory to the clinic.
The opening session consisted of a workshop entitled
“Novel technologies and bioinformatics”. Lance Liotta
(NIH, Bethesda, USA) and Emmanual Petricoin (Center
for Biological Evaluation and Research, FDA, Bethesda,
USA) gave an overview of the advances that can be
applied to molecular analysis of tissues, enabling thou-
sands of molecular events to be studied simultaneously.
The problem of the multistep polygenetic phenotype with
more than one metastasis gene or predictive marker
requires the development of technology that is capable of
studying simultaneous multiple events. Techniques such
as laser capture microdissection (LCM) to isolate the neo-
plastic cells followed by analysis using a combination of
2D gel electrophoresis and surface-enhanced laser des-
orption and ionisation (SELDI) can be used to investigate
the complex protein patterns involved in metastasis as well
as the traditional cDNA microarrays. Not unexpectedly, the
changes identified cluster into four groups concerned with
unrestrained growth, motility, invasion, evasion of host
defenses and angiogenesis.
Genes and environment
Donald Ingber (Harvard Medical School, Boston, USA)
introduced the session by reviewing work on how bio-
chemical pathways may be modified by the structure of a
cell both by its internal structure (principally the cytoskele-
ton) and by external structures in the microenvironment
surrounding a cell. The extracellular-intracellular tensions
are largely maintained by integrins acting as a bridge
between these structures. Reactions inside cells take
place in the solid phase with interacting molecules bound
either directly or indirectly to the cytoskeletal scaffold. For
example, in protein synthesis mRNAs are localised to ver-
tices of the cytoskeleton, if tension imposed by the inte-
grins is prevented, protein synthesis is inhibited. Likewise
transcription of early genes are activated when integrin
ligands bind to receptors. For many growth and differenti-
ation signals, the growth factor/receptor, integrins and
shape of the cell all have to work together and it is this
architectural balance which controls developmental
processes. Disturbance of this architectural balance can
lead to diseases like cancer.
Jean-Paul Thiery (Institut Curie, Paris, France) continued
this theme of cell shape discussing how the shape-change
or plasticity of epithelial cells converting to motile fibroblas-
tic-like cells in a malignant bladder cell model could be
important in the development of cancer. This conversion
could be reversibly triggered by hepatocyte growth
factor/scatter factor (HGF/SF) acting through c-Src and
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the ras-MAPKinase pathway. One of the end products of
these pathways is a transcription factor called slug, related
to snail in Drosophila, which is associated with loss of
desmosomes from the epithelial cells during this conver-
sion process. The epithelial to fibroblastic-like reversible
conversion can also be triggered by structural components
outside the cell such as native collagens and laminin 5.
Thus type I collagen induces specific tyrosine phosphoryla-
tion of focal adhesion kinase (FAK) and paxillin, two pro-
teins present in focal adhesions. Therefore a common focal
point of SF and extracellular architectural control may have
been identified. Overexpression of fibroblast growth
factor-1 (FGF-1) or FGF-2 in these malignant bladder
epithelial cells converts them permanently into the fibrob-
last-like cell type endowed permanently with motile, inva-
sive and metastatic properties. When the released
FGF-1and FGF-2 are inhibited, the angiogenic response is
blocked, but not the fibroblast-like cell shape conversion. It
was originally proposed that the 18KDa form of FGF-2
was responsible for its autocrine and paracrine signalling
effects, but subsequently a nuclear 24KDa moiety was
shown to be responsible for the epithelial to fibroblast con-
version and for the spontaneous metastasis to lungs, but
not for the angiogenic response.
The next two speakers turned to the identification of metasta-
sis-suppressor genes. Carrie Rinker-Schaeffer (University of
Chicago, USA) used the Dunning metastatic prostatic
cancer cell line in rats and microcell transfer to identify
regions of human chromosomes that could suppress its
metastatic activity in rats. Suppressor activity could be identi-
fied on human chromosomes 7, 8, 10, 12, 16 and 17 but not
on chromosome 6. The suppressor activity on chromosome
17 was shown to localise to the MAPKinase kinase 4/stress
activated erk kinase (MKK4/SEK1). In contrast to the chro-
mosome 12 suppressor, where no prostatic carcinoma cells
were found in the lungs in the metastatic assay, MKK4 (chro-
mosome 17) suppressed cells were found in small numbers
in the lung. It was suggested that MKK4 blocked a growth or
cell survival signal that was specifically required in the lungs,
since none of the standard in vitro tests for growth, transfor-
mation, cell motility or angiogenesis showed differences in
the MKK4 transfected cells. Loss of heterozygocity analyses
in human carcinoma suggested that suppressors existed in
similar regions on chromosome 12 and 17.
Andrea McClatchey (MGH Cancer Center, Charlestown,
USA) then discussed the function of the neurofibromato-
sis type 2 (NF2) suppressor, merlin, in tumorigenesis and
metastasis. Merlin is a member of the ezrin, radixin, moesin
(ERM) family of cytoskeleton-membrane linkers that are
thought to maintain and reorganise the cytoskeleton. NF2–
mutant mice were generated and mice heterozygous for
this mutation developed osteosarcomas, fibrosarcomas
and liver carcinomas that exhibited loss of the remaining
NF2 gene. Those cancers were all highly metastatic to the
lung and liver. Analysis of the NF2– cells revealed changes
in cell migration, invasion and survival. In normal cells
phosphorylation of merlin, which can be induced by Rac,
is associated with growth arrest. Moreover, overexpres-
sion of merlin inhibits aspects of Rac signalling and in the
NF2– cells aspects of Rac-mediated signalling are
increased. It would appear that merlin sits at the
cytoskeleton-membrane interface, and its phosphorylation
status causes it to shuttle to and from this point, thus
allowing regulation of the cytoskeleton, perhaps to
produce the plasticity required for metastatic cells, as dis-
cussed by earlier speakers.
Gene expression, host modulation
The search for genes and proteins associated with the
metastatic processes, either in a positive or a negative
way, continued in oral presentations by members in the
Gene Expression-Host Modulation Section. Danny Welch
(Penn State University, Pennsylvania, USA) identified
genes which changed in expression after transfer of
human chromosome 11 which altered a low/moderately
metastatic breast cancer cell line into a highly metastatic
one in nude mice. The highest increase in expression was
observed in osteopontin and then more modest increases
in a ras homologue, osteonectin, calcyclin, casein kinase
and tenascin. He also identified 4 potential suppressors,
a1-antichymotrypsin, PEDF, Kai 1 and a novel BRMS-1
(breast metastasis suppressor-1). BRMS-1 failed to affect
tumour growth, was present in the region close to the
gene for cyclin D1 on chromosome 11 which was modi-
fied in 75% of human breast carcinomas, has casein
kinase and protein kinase C phosphorylation sites, and a
sequence consistent with a leucine zipper transcriptional
complex repressor. In biological assays BRMS-1 restored
gap junction communication in suitably transfected cells.
Erica Sloan (Peter MacCallum Cancer Institute, Mel-
bourne, Australia) using cDNA microarray and candidate
gene approaches in genetically matched mouse mammary
tumour sublines that do or do not metastasize to bone,
found reproducible changes in the levels of caveolin-1
(involved in cholesterol metabolism), protease nexin I,
beta 3 integrin and parathyroid hormone-related protein
(PTHrP). Of the 15 genes initially identified from 5000
genes only 4 scanned positively. Some like PTHrP are not
a primary determinant of metastasis to bone but can mod-
ulate the extent of tumour burden. Mohamed El-Tanani
(University of Liverpool, UK) reported on a system
whereby small fragments of DNA from breast carcinoma
cell lines can upregulate the production of osteopontin
and thereby cause a benign rat mammary cell line to
metastasize when introduced into the mammary fat pad of
syngeneic rats. This effect is accomplished, in part, by
sequestering an inhibitory transcription factor Tcf-4. These
results demonstrate that the transcription factor at the end







































of a protein, osteopontin, important in the metastatic
process, at least in animal models, and suggests that the
Wnt signalling pathway could be important in breast, as it
is in the development of colon cancer.
In addition to the suppressors of metastasis which seemed
to dominate the non mammary gland areas, the metastasis-
promoting molecules were to the fore in the mammary
areas. Thus inhibition of the tumour metastasis-associated
human MTA1 gene (Garth Nicolson, Institute of Molecular
Medicine, Huntington Beach, USA) and the metastasis-
associated S100A4 gene (Berit Mathisen, University of
Tromso, Norway) by targeted antisense and ribozyme tech-
nologies, respectively, showed that they could block
metastatic potential. MTA1 probably functions as a tran-
scription factor involved in cell signalling whereas one of the
effects of S100A4 may be to activate matrix metallopro-
teinases (MMPs). The control of the transcription of these
types of molecules is actively being pursued. For example
the expression of the tumour metastasis suppressor nm23
was shown to be controlled by the transcription factor
CTF/NF1-X and two novel mammary-specific transcription
factors (Taoufik Ouatas, National Cancer Institute,
Bethesda, MD, USA) and the S100A4 could be induced by
interferon-g possibly acting through the STAT1 transcription
factor (Kristin Anderson, Norwegian Radium Hospital, Oslo,
Norway). Immunocytochemical techniques also highlighted
the presence of S100A4 in human breast cancer (Kjetil
Pedersen, Norwegian Radium Hospital, Oslo, Norway)
(Philip Rudland, University of Liverpool, Liverpool, UK).
Preclinical models/clinical studies
George Naumov (London Regional Cancer Center, London,
Canada), a young investigator award winner, reported on an
elegant model for dormancy in breast cancer, in which the
fate of high and low metastatic mouse mammary carcinoma
cell lines could be followed using endogenous-labelling with
green fluorescent protein (GFP) and exogenously-labelled
fluorescent nanospheres to quantitate cellular recovery. Fol-
lowing injections into the mesenteric vein, 50% of the low
metastatic cell line survived as single cells 77 days later,
and even 20% of the high metastatic cell line remained as
single cells 21 days later in the presence of large experi-
mental metastases. The results in this mammary system and
from other nonmammary systems suggested that apparently
nonmetastatic cells could survive for long periods of time in
secondary organs of the host. It was the ability of the cancer
cells to grow into a large micrometastasis prior to vasculari-
sation that was one of the more critical steps in the develop-
ment of secondary tumours.
The importance of micrometastases was continued on the
human scale in this session. Oystein Fodstad (Norwegian
Radium Hospital, Oslo, Norway) made a comparison of
different methods to detect micrometastases on cytospins
of bone marrow and blood, from inter alia breast cancer
patients using immunomagnetic selection. His cell
immunobead detection method gave the best results
enabling 10 times more mononuclear cells to be screened
(~2×10 7) compared to conventional immunocytochemi-
cal detection methods. In many cases where one immuno-
cytochemically positive tumour cell was found,
immunorosetting proved to be negative. There was more-
over a good correlation with detection of micrometastases
by the immunobead detection technique and clinical data.
A similar presentation describing the advantages of using
immunomagnetic methods for the isolation of circulating
cancer cells from prostatic carcinoma patients was given
by Sat Bhattacharya (Memorial Sloan-Kettering Cancer
Centre, New York, USA). He also suggested that the use
of multiple markers greatly enhances the molecular detec-
tion of circulating prostatic carcinoma cells.
Adhesion, motility, proteases
This session was opened with a keynote lecture by Hynda
Kleinman (NIDCR, National Institutes of Health, Bethesda,
USA) who discussed the importance of the basement
membrane in not being just a physical barrier, but actively
enhancing tumour growth, by harbouring angiogenic,
metastatic and tumorigenic factors. Laminin, one of the
most abundant components of the basement membrane,
is especially prominent in influencing tumour growth by
stimulating protease activity, regulating angiogenesis and
tumour cell migration and growth. This group have per-
formed a peptide screen of laminin-1 to identify those pep-
tides responsible for its action. Two synthetic peptides,
A13 and C16, were identified on two different chains of
the laminin molecule. These peptides increased cell adhe-
sion and migration; C16 activated MMP9 in melanoma
cells and both were angiogenic in chick chorioallantoic
membrane assays. They therefore possessed the ability to
promote properties associated with malignant cells. The
receptor for these peptides was identified as integrins
a5b1 and avb3. The sequences for these peptides can be
found in 10/12 of the known isoforms of laminin, inferring
a critical role in the biological activity of laminin.
Kenneth Van Golen (University of Michigan Comprehen-
sive Cancer Center, Ann Arbor, USA) described the iden-
tification of two genes that are consistently altered in the
aggressive disease, inflammatory breast cancer (IBC), one
gene named LIBC (lost in IBC) and the gene for RhoC
GTPase (a member of the Ras superfamily). Human
mammary epithelial cells that stably overexpress RhoC
GTPase were generated and tested in a variety of assays.
The cells showed enhanced invasive and motile properties
and, when examined by electron microscopy, exhibited a
highly polarised cell structure thus confirming the motile
potential of the cell. When the cells were injected into
nude mice, tumours formed in 25% of the mice with 10%
developing micrometastases, suggesting that RhoC over-
expression can contribute to the metastatic phenotype.
Available online http://breast-cancer-research.com/content/3/1/049In a provocative lecture, Ruth Muschel (University of Penn-
sylvania, Philadelphia, USA) challenged the mainstream
view of the mechanism by which metastases form. Instead
of the hypothesis of tumour cells becoming ‘stuck’ in the
small blood vessels with subsequent extravasation leading
to colony formation in the adjacent organ, she proposed
that metastatic cells attach to capillaries with intravascular
proliferation and colony formation subsequently occurring
in the adjacent organ. By injecting GFP-labelled tumour
cells into mouse tail veins, and subsequent visualisation of
the pulmonary circulation by staining the blood vessels
themselves, she observed colony formation intravascularly,
in which extravasation was a rare event. This model of
intravascular metastasis suggests that early colonies
would be especially vulnerable to intravascular drugs.
Signalling, cytoskeleton, motility
Ian Hart (Rayne Institute, London, UK) described studies
investigating the receptor for hyaluronic acid mediated
motility (RHAMM), originally thought to be a membrane
bound protein and present in human tumour cells.
However, this protein has actually been shown to be an
intracellular protein and thus a name change to intracellular
hyaluronic acid binding protein (IHABP) has been sug-
gested. RHAMM has two microtubule binding domains and
is also capable of binding to actin filaments thus potentially
having a role in tumour cell motility. Using a polyclonal anti-
body, lobular and ductal mammary carcinomas were exam-
ined for RHAMM expression. There was significantly lower
expression of RHAMM in the cytoplasm of cells, but a
higher expression in the trabeculae and invasive edge of
the tumour islands. Thus RHAMM could prove important in
contributing to the invasiveness of tumour cells.
Paulo Comoglio (University of Torino, Candiolo, Italy)
reported on the mesenchyme-produced HGF/SF which,
working through the MET receptor, is able to accomplish
apparently independent biological responses: cell prolifer-
ation, survival, motility/invasion, and cell polarity, leading
normally to invasive cell growth. This induces branching
morphogenesis (tubulogenesis) on mammary epithelial
cells. MET and its two closely related family members,
RON and SEA, feature unique signal transduction proper-
ties, as their cytoplasmic tails contain a two-tyrosine multi-
functional docking site that binds multiple SH2-containing
intracellular signal transducers. Dissection of the signalling
pathways has shown that ras, PI3-K and STAT were
responsible for growth, scattering/survival and polarity/
morphogenesis, respectively. PI3-K operated through Rac
for scattering leading to cell motility/invasion and through
Akt for apoptosis protection (anoikis). Dr Comoglio also
reported on the discovery of the Sex/plexins, sharing
homology with the extracellular domain of MET and their
ligands, the semaphorins, which in mammalian cells
control cell-cell repulsion, a process reminiscent of “scat-
tering”. Thus the name of the original receptor MET may
not be inappropriate for a class of large receptors produc-
ing invasive growth in diverse situations.
Multiple functions of proteases
This session emphasised that tumour initiation is not just
caused by a breakdown of connective tissue but involves
many levels and interactions between multiple cell types.
Lynn Matrisian (Vanderbilt University, Nashville, USA)
began by contesting the hypothesis that MMPs are only
involved in degradation of the basement membrane and
extracellular matrix (ECM). She showed that Matrilysin
(MMP 7), unlike other MMPs, is virtually always expressed
in epithelial cells and has been shown to cleave mem-
brane bound Fas Ligand (Fas L), releasing soluble apopto-
sis-inducing Fas L. However, when normal murine
mammary gland cells were stably transfected with
matrilysin, a reduced sensitivity to Fas-mediated apoptosis
in response to matrilysin treatment was demonstrated.
This reduced sensitivity to apoptosis-inducing agents
could contribute to tumour progression by the develop-
ment of cells that are less likely to undergo apoptosis for
example in response to DNA damage.
Bill Stetler-Stevenson (NCI, Bethesda, USA) followed with
the conflicting roles of tissue inhibitors of matrix metallo-
proteinases (TIMPs). TIMPs appear to act as enhancers of
cell growth in tumour cells and fibroblasts but inhibit the
growth of cultured endothelial cells. TIMPs can directly
inhibit FGF and VEGF stimulated growth of endothelial
cells thus acting as an angiogenesis inhibitor. In trying to
elucidate the conflicting roles of TIMPs, this group have
studied the effects of TIMP on a human B cell lymphoma
model. When grown subcutaneously in nude mice, TIMP-1
transfected cells initially have an accelerated growth,
however at later times the tumours necrose and regress
due to the anti-angiogenic effects of TIMP-1 on endothe-
lial cells. In a second model system using a TIMP-2 mutant
devoid of MMP inhibitor activity they demonstrated that
TIMP-2 inhibition of angiogenesis was independent of
MMP inhibition. These results suggest that TIMPs can
modify cell growth independently of MMP activity.
The role of heparanase was the subject of the lecture by
Israel Vlodaysky (Hadassah University Hospital, Jerusalem,
Israel). The heparanase gene is found in highly metastatic
human breast cancer cells, but not in normal epithelial
cells. In biopsy specimens, immunocytochemical staining
for heparanase was especially pronounced in invasive
ductal mammary carcinomas. Overexpression of
heparanase leads to increased metastasis and mortality in
mice. It has been postulated that heparanase may release
growth factors such as FGF from the surrounding tissue
(eg basement membrane) thus initiating angiogenesis and
contributing to tumourigenesis. In transgenic mice that
overexpress the heparanase gene, staining is seen in the
Breast Cancer Research    Vol 3 No 1 Taylor and Rudlandmammary gland and could possibly represent a premalig-
nant state. Knock out animal models of this gene are being
developed and will provide an indication of the importance
of heparanase.
Molecular crosstalk and angiogenesis
Following the plenary lecture by Mary Hendrix (University
of Iowa, Iowa City, USA), in which her work on vasculo-
genic mimicry was elegantly explained [1], the main theme
of this session was the subject of inhibitors of angiogene-
sis and therapies.
The antiangiogenic property of thrombospondin-1 (TSP-1)
was described by Giulia Taraboletti (Mario Negri Institute,
Bergamo, Italy). In a series of experiments, it was shown
that TSP-1 inhibits the binding of FGF-2 to its low affinity
receptors present on endothelial cells. TSP-1 also released
ECM bound FGF-2 as a TSP-1/FGF-2 complex, which has
subsequently been shown to stimulate endothelial cell pro-
liferation. Thus, by reducing the actions of TSP-1 on the
ECM, this could represent another potential anti-angio-
genic mechanism for TSP-1.
The role of oxygen radicals in angiogenesis was
addressed by Moshe Marikovsky (Hebrew University,
Jerusalem, Israel). Oxygen radicals are a by-product of
normal cell metabolism. Mice overexpressing the enzyme
superoxide dismutase (SOD-1) showed increased angio-
genesis following FGF administration. This effect was
attenuated by disulfiram, a specific inhibitor of SOD-1.
Disulfiram also induced apoptosis in cultured endothelial
cells, indicating its possible mechanism of action. It has
been shown that proliferating endothelial cells are a target
for oxygen radicals and thus have increased levels of
SOD-1. These results imply that targeting the SOD-1
pathway may have potential for inhibition of metastasis.
GFP labelled tumour cells were utilized in the in vivo
studies by the group of Robert Hoffman (Anticancer Inc,
San Diego, USA). When these labelled cells were injected
into the tail vein of mice, the growth of the tumour cells
and metastases were clearly visable by whole-body
imaging. Vascularisation could be detected by the con-
trast of the dark vessels against the highlighted fluores-
cent tumours. This system was used to study transplanted
Lewis lung carcinoma cells, and tracked the tumour cells
crossing the diaphragm and using the lymphatic system to
travel to the contralateral lung. This system could poten-
tially be useful in the study of angiogenesis inhibitors.
Sofia Mejaver (University of Michigan Medical Center, Ann
Arbor, USA) described investigations into the anti-angio-
genic properties of copper deficiency. Tetrathiomolybdate
(TM), a copper chelator approved for human use, was
administered to female MMTV-HER2/neu transgenic mice
that had developed large mammary tumours. Administra-
tion of TM arrested the growth of these tumours, therefore
implying that copper deficiency inhibits de novo clinically
significant mammary tumours. Clinical trials of TM have
begun, showing some initial promising results, albeit in a
very small number of patients.
Molecular therapeutics
William Fogler (Entremed Inc, Rockville, USA) described
the latest developments on the role of endostatin and its
potential as an anti-angiogenesis therapy. Phage display
techniques were utilized to elucidate the molecular target
of endostatin. A binding protein sharing epitopes with
tropomyosin type 3 was identified. It was also shown that
endostatin and tropomyosin colocalise to the myofilaments
and there is a physical interaction between these two in
cultured human umbilical vein endothelial cells, although it
remains to be determined whether this truly represents the
site of action of endostatin.
Dennis Slamon (UCLA, Los Angeles, USA) gave the final
talk and highlight of this session which encompassed both
the discovery of the overexpression of the growth factor
receptor c-erbB-2 in 25–30% of patients with invasive
breast cancer and the use of the anti-HER-2/neu human-
ised antibody Herceptin in mouse and in man. The major
Phase III trial in 469 c-erbB-2-positive patients comparing
the best available standard therapy versus best plus Her-
ceptin showed that the latter improved objective response
rates by 54%, response duration by 58% and time to pro-
gression by 65%. Preliminary analysis showed an
improved 1 year survival of 11% and at 30 months, 25%.
There was little change with Herceptin alone. These
figures may be improved if the selection criterion per
patient is based on gene amplification rather than overex-
pression of c-erbB-2. The major problem in its use with
anthracyclines was cardiac toxicity in almost 40% of
women, but this may be reduced by combining Herceptin
with other agents. The actual mechanism of Herceptin
does not appear to depend on the immune system since it
is active in immunodeficient mice and removal of its Fc
portion fails to inhibit its effects. It is thought that Her-
ceptin blocks dimerisation/oligermerisation of receptors
causing aberrant intracellular signalling, but the precise
mechanism has yet to be elucidated. Herceptin is there-
fore one of the first biological response modifiers to have
shown some clinical success and as such has led to its
approval in the treatment of patients with c-erbB-2 overex-
pressing breast cancers.
Angiogenesis: conundrums and controversies
Roy Bicknell (ICRF, Molecular Oncology Laboratories,
Oxford, UK) continued on the theme of oxygen free
radical stress by reporting on the actions of thymidine
phosphorylase (TP). TP is an angiogenic factor, first iso-
lated from platelets, and has been shown to be elevated in








































hin carcinomas, including breast. To elucidate the mecha-
nism of action of TP, expression of haem-oxygenase, a
marker of oxidative stress, was examined in carcinoma
cells. TP increased haem-oxygenase levels, thus inducing
oxidative stress by the generation of free radicals. Subse-
quently, secretion of angiogenic factors such as vascular
endothelial growth factor and interleukin-8 are increased
and MMPs are induced, ultimately resulting in the forma-
tion of blood vessels.
Conclusion
The VIII International Congress of the Metastasis
Research Society terminated where it began in London 20
years earlier. Kurt Hellmann (St John’s Institute of Derma-
tology, London, UK), one of the founding members of the
Society, commented that in the beginning there was little
interest in the study of metastatic processes per se. In
those days the major research efforts were concentrated
on unravelling the uncontrolled growth of tumours. This
conference, however, demonstrated that metastasis
research is now actively pursued throughout the world, in
various guises, as the key to producing potentially new
therapies directed at eradicating the major forms of
cancer. Research on the uncontrolled growth of tumours
has spread, it would appear, to almost all aspects of
developmental biology not only to the cancer cells them-
selves, but also to the host organs in which the metas-
tases develop. Thus the “seed and soil” hypothesis first
expounded by Paget more than a century ago for the
process of metastasis, is now coming to fruition, as out-
lined by Dr Fidler in his Award Lecture. The generation of
genomic instability followed by selection of cells capable
of undergoing the steps of the metastatic cascade means
that parallel pathways with perhaps different balances of
regulatory molecules may underlie the overall process,
even for a cancer like that of invasive ductal carcinoma of
the breast. The use of modern genomic and proteomic
techniques to unravel the potential multitude of molecules
involved in the metastatic cascade is now proving invalu-
able. The new systemic drugs that are being developed
against metastatic disease are targeting and will continue
to target the new regulatory molecules as they are discov-
ered. However, many of these new drugs are not cytotoxic
but rather cytostatic in nature. Thus the question raised by
Dr Carter in his Award Lecture as to whether the cytotoxic
endpoint of objective response can be used for decision
making in the development of such therapies is pertinent
to this area of research. One felt on leaving this Confer-
ence that, unlike many cancer conferences, a rational view
on how cancer could spread had been presented.
Whether the plethora of results presented at this confer-
ence is relevant to specific human cancers and can be
utilised to produce successful treatments of metastatic
disease only time will tell.
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